Fecal occult blood testing for colorectal cancer - Can we afford to do this?
Fecal occult blood testing for colorectal cancer - Can we afford to do this?
复制标题
DOI：
10.1016/s0889-8553(05)70282-x
复制
发表时间：
1997-03-01
影响因子：
3.7
通讯作者：
Ahlquist, DA
中科院分区：
文献类型：
--
作者：
Ahlquist, DA
粪血是无症状结直肠肿瘤本质上不敏感和非特异性的标记物。因此，粪便潜血测试 (FOBT) 的使用必然会限制筛查应用的有效性和效率。 FOBT 筛查可能会适度降低结直肠癌特异性死亡率，但它既不会改变结直肠癌发病率，也不会改变总体死亡率。 FOBT 筛查带来的成本是巨大的，而筛查引起的死亡率在多大程度上抵消了任何益处仍不得而知。在没有明确证明 FOBT 筛查的净效益的情况下，这项昂贵工作的承受能力可能会受到合理质疑。
Fecal blood is an inherently insensitive and nonspecific marker for asymptomatic colorectal neoplasia. As such, use of fecal occult blood tests (FOBTs) necessarily limits the effectiveness and efficiency of a screening application. FOBT screening may result in a modest reduction in colorectal cancer-specific mortality, but it alters neither colorectal cancer incidence nor overall mortality. Costs resulting from FOBT screening are substantial, and the extent to which screen-induced mortality offsets any benefits remains unknown. In the absence of a clearly demonstrated net benefit with FOBT screening, affordability of this expensive effort can be legitimately questioned.